Medtronic Announces New Outcomes-Based Agreement with Aetna

Today we announced an outcomes-based agreement with Aetna for type 1 and type 2 diabetes patients who currently receive multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard™ Technology – the only feature available in the U.S. that takes action against lows,[i] and the only one proven to reduce the frequency of nighttime low episodes which can be life threatening if not managed appropriately.i,[ii],[iii]

The agreement ties a component of Medtronic’s reimbursement to successfully meeting clinical improvement thresholds, with the goal of elevating patient experience, improving clinical outcomes and lowering the total cost of care. This reinforces our strong confidence in the outcomes delivered by our market-leading solutions, which have been demonstrated through a strong body of compelling and growing clinical evidence. Through this agreement, Aetna members will have access to our advanced diabetes technologies and comprehensive support services, including our groundbreaking Minimed® 670G system* featuring our advanced SmartGuard HCL technology and Guardian Sensor 3 – the first and only system that constantly self-adjusts to keep patients’ blood sugar levels in range based on their personalized needs.

This agreement is the first step in partnering with Aetna to shift healthcare towards value-based models that facilitate patient access to the most advanced diabetes management solutions across the care continuum that not only ensure outcomes, but enhance patient experience and lower the overall cost of care for this chronic and burdensome disease.

Our goal is to continue to lead by driving innovation that demonstrably improves patient outcomes, elevates patient experience and lowers the total cost of care. We have the only insulin delivery systems in the world that take action based on sensor values. The growing body of clinical evidence demonstrating the benefits of our proprietary SmartGuard™ Technology is compelling and we are pleased to work with Aetna to align incentives around the technologies that make the biggest difference for patients and for the health system.

[1] < 65 mg/dL, measured in sensor glucose values.

[ii] Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–232.

[iii] Based upon limited sample size and duration of ASPIRE In-Home study.


Print This Post Print This Post
Latest Comments
  1. Kelley Hughes
    • Danielle Swanson

Post A Comment

Your email address will not be published. Required fields are marked *